Showing 2461-2470 of 5623 results for "".
- Pfizer CEO Predicts Third COVID-19 Vaccine Booster “Likely” Needed Within Yearhttps://modernod.com/news/pfizer-ceo-predicts-third-covid-19-vaccine-booster-likely-needed-within-year/2479086/Pfizer CEO Albert Bourla believes it will probably be necessary for people to receive yet another dose of COVID-19 vaccine within a year of being fully vaccinated in order to stave off infection, according to recent taped comments that were made public on Thursday. “There will be likely a n
- ProtoKinetix Engages Multi-National Partner for Formulation of Topical Drug to Treat DED & Ocular Inflammationhttps://modernod.com/news/protokinetix-engages-multi-national-partner-for-formulation-of-topical-drug-to-treat-ded-ocular-inflammation/2479083/ProtoKinetix announced that it has engaged a global pharmaceutical company to develop the formulation as a topical ocular drug for the treatment of dry eye disease (DED) and ocular inflammation using AAGP. For the development of this drug for DED to date the company has completed:
- Lantronix Contributes to eSight Design, Enabling Individuals With Serious Visual Impairment to Seehttps://modernod.com/news/lantronix-contributes-to-esight-design-enabling-individuals-with-serious-visual-impairment-to-see/2479082/Lantronix announced that its engineering services team supported eSight Corp. in the development of an enhanced vision device that enables individuals with serious visual impairment to see. eSight was recently recognized as a manufacturer of the Best Wearable/Healthcare Hardware/Soft
- Santen Announces Global Research Initiative to Study and Develop New Treatments for Glaucomahttps://modernod.com/news/santen-announces-global-research-initiative-to-study-and-develop-new-treatments-for-glaucoma/2479067/Santen announced a research initiative with scientists from Massachusetts Eye and Ear, and Ulster University, UK, to research and develop novel treatments for glaucoma. The aim
- Pfizer, BioNTech Seek Expanded Emergency Use of COVID-19 Vaccine in Younger Adolescentshttps://modernod.com/news/pfizer-biontech-seek-expanded-emergency-use-of-covid-19-vaccine-in-younger-adolescents/2479068/Pfizer and BioNTech said they have asked the FDA to amend the emergency-use authorization (EUA) for their coronavirus vaccine BNT162b2 to include use in adolescents 12-to-15 years of age, adding they will be making similar requests to other global regulatory bodies in the coming days. The mRNA-ba
- NEI Joins Call for Standardization of Ophthalmic Imaging Deviceshttps://modernod.com/news/nei-joins-call-for-standardization-of-ophthalmic-imaging-devices/2479064/The National Eye Institute (NEI), part of the National Institutes of Health, is joining the American Academy of Ophthalmology (AAO) and others in calling for imaging device makers to standardize their data formatting. Such standardization is expected to enable comm
- FDA Approves Bausch + Lomb ClearVisc Dispersive Ophthalmic Viscosurgical Device (OVD)https://modernod.com/news/fda-approves-bausch-lomb-clearvisc-dispersive-ophthalmic-viscosurgical-device-ovd/2479058/Bausch + Lomb, announced that the FDA has approved ClearVisc dispersive ophthalmic viscosurgical device (OVD) for use in ophthalmic surgery. “OVDs play a critical role in ophthalmic surgery, and ClearVisc offers surgeons unique advantages that are designed to contribute to surgical safety
- Second Sight Medical Products Names Dean Baker and Alexandra Larson to its Board of Directorshttps://modernod.com/news/second-sight-medical-products-names-dean-baker-and-alexandra-larson-to-its-board-of-directors/2479051/Second Sight Medical Products announced that the company’s Board of Directors has appointed two new members, Dean Baker, PhD, and Alexandra Larson. Dr. Baker has also been appointed to the Audit Committee of the Board. “We are honored and excited to add these two very talented individuals
- ForeseeHome AMD Home Monitoring Real-World Data Analysis Demonstrates Substantial Benefit for Patients’ Visionhttps://modernod.com/news/foreseehome-amd-home-monitoring-real-world-data-analysis-demonstrates-substantial-benefit-for-patients-vision/2479053/Real-world data on the performance of the ForeseeHome AMD Monitoring Program, a home-based diagnostic that helps detect the conversion from intermediate dry to wet age-related macular degeneration (AMD), was recently published in the Journal of Clinical Medicine as part of the “Diagnosis,
- AffaMed Therapeutics Completes $170 Million Series B Financing to Further Development of Ophthalmic and Neuroscience Pipelinehttps://modernod.com/news/affamed-therapeutics-completes-170-million-series-b-financing-to-further-development-of-ophthalmic-and-neuroscience-pipeline/2479029/AffaMed Therapeutics announced the completion of over $170 million in Series B financing. Proceeds from the financing will be used to advance clinical development of AffaMed’s pipeline of innovative therapeutic candidates, progress business development and partnering activities, and support